Loading...
NPI 1568994879 · Southfield, MI · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
North West Labs, Inc. is a clinical medical laboratory provider located in Southfield, Michigan. This profile covers 34 Medicare and 90 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | North West Labs, Inc. |
| Address | 29580 Northwestern Hwy Ste 120 |
| City | Southfield |
| State | MI |
| ZIP | 48034 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | March 28, 2017 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $10.9M |
| Medicare | $1.4M |
NORTH WEST LABS, INC. is a Clinical Medical Laboratory located in SOUTHFIELD, MI with an NPI enumerated on 2017-03-28 (~9 years ago). The taxonomic and claims mix (heavy laboratory CPT/HCPCS codes) is consistent with an independent diagnostic lab focused on molecular infectious disease testing and definitive toxicology panels rather than a clinician office or hospital-based lab.
Medicare revenue is tightly concentrated: the precomputed top three Medicare codes account for 91.6% of this provider's total Medicare revenue. The three revenue leaders on Medicare are G0483 ($984.5K, 68.2% of Medicare revenue), G0482 ($185.3K, 12.8%), and G0481 ($153.5K, 10.6%), indicating that a small set of definitive drug-testing services drive most Medicare receipts.
The Medicare code mix (G0483, G0482, G0481) points to an operational emphasis on high-complexity definitive drug testing methods (GC/MS, LC/MS) and specimen validity testing; lower-paid routine chemistry and hematology panels (for example 85025, 80053) appear only as minor revenue contributors. The presence of COVID molecular codes (U0003, 87635) at much smaller Medicare dollars suggests some infectious disease testing capacity but not the primary Medicare revenue source.
Medicaid revenue is dominated by COVID and specimen collection activity: the precomputed top three Medicaid codes account for 81.5% of Medicaid revenue. The Medicaid leaders are U0003 ($5.8M, 53.3% of Medicaid revenue), G0483 ($2.2M, 20.1%), and G2023 ($883.9K, 8.1%), showing very large volumes of high-throughput SARS–CoV–2 testing and associated specimen collection alongside definitive drug testing.
Operational scale differs sharply by payer: total Medicaid revenue ($10.9M) is an order of magnitude larger than total Medicare revenue ($1.4M), making Medicaid the dominant payer for this lab. That payer mix indicates the business is effectively Medicaid-driven in scale and would be sensitive to state Medicaid policy or volume changes.
On competitive standing, the provider shows a mixed picture across payers. For Medicare, G0483 ranks #22 of 1063 providers nationally (98th percentile) but is characterized in the data as "typical, unremarkable volume for this code," suggesting high relative national placement without exceptional code-specific prevalence claims; G0482 and G0481 also sit in the mid-to-high percentiles (95th and 97th).
In-state Medicaid rankings show clear market leadership for COVID services: U0003 ranks #3 of 157 providers in-state (98th percentile; labeled an "extreme outlier, far above typical state volume for this code") and G2023 ranks #1 of 159 providers in-state (100th percentile; labeled an "extreme outlier, far above typical state volume for this code"). Together these rankings indicate this lab is a major statewide player for SARS–CoV–2 testing and specimen collection.
The provider’s revenue profile is highly concentrated around a few service lines (top-3 share 91.6% Medicare; top-3 share 81.5% Medicaid), which implies operational specialization but also revenue exposure. Because large shares of Medicaid receipts come from pandemic-era testing codes (U0003, G2023) and a small number of definitive drug-testing codes carry most Medicare revenue, changes in public-health testing demand or payer coverage policies for those codes could materially affect overall revenue.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
34 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4,070 | $240 | $984.5K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 950 | $200 | $185.3K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,000 | $150 | $153.5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 410 | $110 | $46.4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 330 | $70 | $24.6K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 170 | $50 | $8.3K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 80 | $90 | $7.8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 290 | $30 | $7.2K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 510 | $10 | $4.1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 400 | $10 | $4K |
Showing 1–10 of 34
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 34 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
34 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0483 | 2 | 20 | 140 | $240 | $206.2K |
| G0482 | 7 | 50 | 140 | $190 | $109.1K |
| G0480 | 12 | 30 | 270 | $110 | $63.5K |
| G0481 | 6 | 40 | 120 | $150 | $62.1K |
| U0003 | 9 | 30 | 60 | $70 | $17.6K |
| 82306 | 70 | 180 | 40 | $30 | $8.9K |
| 84443 | 63 | 300 | 70 | $20 | $6.2K |
| U0005 | 11 | 30 | 150 | $20 | $5.9K |
| 80053 | 54 | 360 | 120 | $10 | $5.6K |
| 82607 | 49 | 150 | 40 | $10 | $5.4K |
Showing 1–10 of 34
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
90 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 90,920 | $60 | $5.8M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 19,100 | $120 | $2.2M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 49,100 | $20 | $883.9K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 10,050 | $60 | $632.8K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 16,430 | $40 | $607.9K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 10,910 | $30 | $305.4K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,960 | $50 | $268.3K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 1,610 | $30 | $43.4K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 1,230 | $30 | $37K |
| 87804 | The analyst performs an immunoassay with direct optical, meaning visual, observation to detect influenza, also called flu, in a patient sample, typically a throat or nasal swab or nasal washings. | 4,700 | $10 | $32.9K |
Showing 1–10 of 90
How this provider's Medicaid billing volume and revenue compare to other Michigan providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Michigan median
90 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 7 | 60 | 1,310 | $130 | $1.1M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 10 | 70 | 680 | $100 | $604K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 3 | 160 | 2,720 | $60 | $546.6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 10 | 50 | 650 | $80 | $298.5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 12 | 150 | 2,250 | $30 | $202.4K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 141 | 180 | 2,600 | $20 | $162K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 143 | 190 | 2,610 | $20 | $160.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 44 | 240 | 2,430 | $20 | $152.2K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 148 | 270 | 1,950 | $10 | $131.1K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 120 | 180 | 2,050 | $10 | $120.4K |
Showing 1–10 of 90
Other providers in the same ZIP code as North West Labs, Inc., ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Pro Care Unlimited, LLC | MI | Home Health Agency | $0 | $216M |
| Coordinated Community Living | MI | Home Health Agency | $0 | $85.8M |
| Vhs Physicians Of Michigan | MI | Internal Medicine Physician | $0 | $73.9M |
| Angels' Place | MI | Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility | $0 | $18.1M |
| Great Lakes Surgical Center LLC | MI | Ambulatory Surgical Clinic/Center | $82.6K | $4M |
| City Of Southfield | MI | Ambulance | $845.3K | $1.8M |
| Biogenetics Laboratories, Inc. | MI | Clinical Medical Laboratory | $648.4K | $1.9M |
| Michael Ober | MI | Ophthalmology Physician | $1.8M | $0 |
| Robert Scribner | MI | Gerontology Nurse Practitioner | $1.5M | $0 |
| Darrin Levin | MI | Ophthalmology Physician | $1.5M | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.